{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:01:00Z","timestamp":1790269260995,"version":"4.1.0"},"reference-count":91,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["K24 MHO79510"],"award-info":[{"award-number":["K24 MHO79510"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["biologicalpsychiatryjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.biopsych.2014.08.024","type":"journal-article","created":{"date-parts":[[2014,9,16]],"date-time":"2014-09-16T01:38:15Z","timestamp":1410831495000},"page":"685-692","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Imaging Biomarkers Associated With Cognitive Decline: A Review"],"prefix":"10.1016","volume":"77","author":[{"given":"Jonathan","family":"McConathy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvette I.","family":"Sheline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopsych.2014.08.024_bib1","article-title":"Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer\u2019s disease [published online ahead of print May 2]","author":"Blennow","year":"2014","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.biopsych.2014.08.024_bib2","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00401-013-1151-4","article-title":"Longitudinal change in CSF tau and A\u03b2 biomarkers for up to 48 months in ADNI","volume":"126","author":"Toledo","year":"2013","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.biopsych.2014.08.024_bib3","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2217\/pme.10.53","article-title":"US FDA and personalized medicine: In vitro diagnostic regulatory perspective","volume":"7","author":"Tevak","year":"2010","journal-title":"Per Med"},{"key":"10.1016\/j.biopsych.2014.08.024_bib4","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0197-4580(98)00022-0","article-title":"Consensus report of the Working Group on: \u201cMolecular and Biochemical Markers of Alzheimer\u2019s Disease\u201d[Erratum in: Neurobiol Aging May-Jun;19(3):285]","volume":"19","year":"1998","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.biopsych.2014.08.024_bib5","first-page":"125","article-title":"Clinical features and multidisciplinary approaches to dementia care","volume":"4","author":"Grand","year":"2011","journal-title":"J Multidiscip Health"},{"issue":"3 suppl","key":"10.1016\/j.biopsych.2014.08.024_bib6","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3233\/JAD-2006-9S347","article-title":"Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the Consortium on DLB International Workshop","volume":"9","author":"McKeith","year":"2006","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.biopsych.2014.08.024_bib7","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.biopsych.2014.08.024_bib8","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1212\/WNL.51.6.1546","article-title":"Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria","volume":"51","author":"Neary","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.biopsych.2014.08.024_bib9","series-title":"Dementia","year":"2010"},{"key":"10.1016\/j.biopsych.2014.08.024_bib10","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.biopsych.2014.08.024_bib11","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.biopsych.2014.08.024_bib12","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/ana.22628","article-title":"An operational approach to National Institute on Aging\u2013Alzheimer\u2019s Association criteria for preclinical Alzheimer disease","volume":"71","author":"Jack","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1016\/j.biopsych.2014.08.024_bib13","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/j.1532-5415.1999.tb02571.x","article-title":"Clinico-neuropathological correlation of Alzheimer\u2019s disease in a community-based case series","volume":"47","author":"Lim","year":"1999","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.biopsych.2014.08.024_bib14","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/JGP.0b013e3181629971","article-title":"Clinical criteria for the diagnosis of Alzheimer disease: Still good after all these years","volume":"16","author":"Ranginwala","year":"2008","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.biopsych.2014.08.024_bib15","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1212\/WNL.56.9.1143","article-title":"Practice parameter: Diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"56","author":"Knopman","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.biopsych.2014.08.024_bib16","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/NEN.0b013e31824b211b","article-title":"Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers","volume":"71","author":"Beach","year":"2012","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.biopsych.2014.08.024_bib17","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1202753","article-title":"Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease","volume":"367","author":"Bateman","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopsych.2014.08.024_bib18","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.neurobiolaging.2010.04.007","article-title":"Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging","volume":"31","author":"Rowe","year":"2010","journal-title":"Neurobiol Aging"},{"issue":"pt 4","key":"10.1016\/j.biopsych.2014.08.024_bib19","first-page":"1067","article-title":"MRI of hippocampal volume loss in early Alzheimer\u2019s disease in relation to ApoE genotype and biomarkers","volume":"132","author":"Schuff","year":"2009","journal-title":"Brain"},{"issue":"pt 5","key":"10.1016\/j.biopsych.2014.08.024_bib20","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/brain\/awn320","article-title":"Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects","volume":"132","author":"Mormino","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.biopsych.2014.08.024_bib21","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/ana.21843","article-title":"APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging","volume":"67","author":"Morris","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.biopsych.2014.08.024_bib22","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.tins.2011.05.005","article-title":"Neuroimaging markers for the prediction and early diagnosis of Alzheimer\u2019s disease dementia","volume":"34","author":"Ewers","year":"2011","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.biopsych.2014.08.024_bib23","first-page":"1124","article-title":"Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI","volume":"80","author":"Vos","year":"2013","journal-title":"Am Acad Neuro"},{"key":"10.1016\/j.biopsych.2014.08.024_bib24","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/gps.3829","article-title":"The development of effective biomarkers for Alzheimer\u2019s disease: A review","volume":"28","author":"Henry","year":"2013","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.biopsych.2014.08.024_bib25","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev-clinpsy-050212-185535","article-title":"Neuroimaging and other biomarkers for Alzheimer\u2019s disease: The changing landscape of early detection","volume":"9","author":"Risacher","year":"2013","journal-title":"Annu Rev Clin Psychol"},{"key":"10.1016\/j.biopsych.2014.08.024_bib26","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1212\/WNL.0b013e318281ccd3","article-title":"Cerebral atrophy in mild cognitive impairment and Alzheimer disease: Rates and acceleration","volume":"80","author":"Leung","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.biopsych.2014.08.024_bib27","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/WAD.0b013e318260a79a","article-title":"The value of hippocampal and temporal horn volumes and rates of change in predicting future conversion to AD","volume":"27","author":"Macdonald","year":"2013","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"1124","key":"10.1016\/j.biopsych.2014.08.024_bib28","first-page":"e1131","article-title":"Localized hippocampus measures are associated with Alzheimer pathology and cognition independent of total hippocampal volume","volume":"33","author":"Carmichael","year":"2012","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.biopsych.2014.08.024_bib29","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.neuroimage.2012.04.056","article-title":"Combining MRI and CSF measures for classification of Alzheimer\u2019s disease and prediction of mild cognitive impairment conversion","volume":"62","author":"Westman","year":"2012","journal-title":"Neuroimage"},{"key":"10.1016\/j.biopsych.2014.08.024_bib30","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1001\/archneurol.2011.167","article-title":"The dynamics of cortical and hippocampal atrophy in Alzheimer disease","volume":"68","author":"Sabuncu","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1016\/j.biopsych.2014.08.024_bib31","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1212\/WNL.0b013e3182166e96","article-title":"Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults","volume":"76","author":"Dickerson","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.biopsych.2014.08.024_bib32","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1148\/radiol.11101975","article-title":"Mild cognitive impairment: Baseline and longitudinal structural MR imaging measures improve predictive prognosis","volume":"259","author":"McEvoy","year":"2011","journal-title":"Radiology"},{"key":"10.1016\/j.biopsych.2014.08.024_bib33","doi-asserted-by":"crossref","first-page":"20954","DOI":"10.1073\/pnas.0906053106","article-title":"Subregional neuroanatomical change as a biomarker for Alzheimer\u2019s disease","volume":"106","author":"Holland","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopsych.2014.08.024_bib34","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.neurobiolaging.2006.05.006","article-title":"CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment","volume":"28","author":"Bouwman","year":"2007","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.biopsych.2014.08.024_bib35","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1212\/WNL.0b013e3181af79fb","article-title":"MRI and CSF biomarkers in normal, MCI, and AD subjects: Predicting future clinical change","volume":"73","author":"Vemuri","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.biopsych.2014.08.024_bib36","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1212\/WNL.0b013e3182563bbe","article-title":"Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease","volume":"78","author":"Knopman","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.biopsych.2014.08.024_bib37","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1523\/JNEUROSCI.4437-12.2013","article-title":"Brain microstructure reveals early abnormalities more than two years prior to clinical progression from mild cognitive impairment to Alzheimer\u2019s disease","volume":"33","author":"Douaud","year":"2013","journal-title":"J Neurosci"},{"key":"10.1016\/j.biopsych.2014.08.024_bib38","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.neurobiolaging.2008.08.010","article-title":"Evidence that volume of anterior medial temporal lobe is reduced in seniors destined for mild cognitive impairment","volume":"31","author":"Martin","year":"2010","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.biopsych.2014.08.024_bib39","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/1741-7015-10-127","article-title":"Preclinical Alzheimer disease: Identification of cases at risk among cognitively intact older individuals","volume":"10","author":"Lazarczyk","year":"2012","journal-title":"BMC Med"},{"key":"10.1016\/j.biopsych.2014.08.024_bib40","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3389\/fncel.2014.00095","article-title":"Why looking at the whole hippocampus is not enough\u2014a critical role for anteroposterior axis, subfield and activation analyses to enhance predictive value of hippocampal changes for Alzheimer\u2019s disease diagnosis","volume":"8","author":"Maruszak","year":"2014","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.biopsych.2014.08.024_bib41","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/01.wnl.0000259542.54830.34","article-title":"Brain structural alterations before mild cognitive impairment","volume":"68","author":"Smith","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.biopsych.2014.08.024_bib42","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.neurobiolaging.2007.11.028","article-title":"Prefrontal cortex atrophy predicts dementia over a six-year period","volume":"30","author":"Burgmans","year":"2009","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.biopsych.2014.08.024_bib43","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1212\/WNL.0b013e31823efc6c","article-title":"MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults","volume":"78","author":"Dickerson","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.biopsych.2014.08.024_bib44","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/ana.22333","article-title":"Amyloid-b associated cortical thinning in clinically normal elderly","volume":"69","author":"Becker","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.biopsych.2014.08.024_bib45","doi-asserted-by":"crossref","first-page":"S155","DOI":"10.3233\/JAD-2012-120730","article-title":"Functional MRI of mnemonic networks across the spectrum of normal aging, mild cognitive impairment, and Alzheimer\u2019s disease","volume":"31","author":"Chhatwal","year":"2012","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.biopsych.2014.08.024_bib46","doi-asserted-by":"crossref","first-page":"17680","DOI":"10.1523\/JNEUROSCI.4740-11.2011","article-title":"Hippocampal hyperactivation associated with cortical thinning in Alzheimer\u2019s disease signature regions in non-demented elderly adults","volume":"31","author":"Putcha","year":"2011","journal-title":"J Neurosci"},{"key":"10.1016\/j.biopsych.2014.08.024_bib47","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.biopsych.2012.11.028","article-title":"Resting state functional connectivity in preclinical Alzheimer\u2019s disease","volume":"74","author":"Sheline","year":"2013","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2014.08.024_bib48","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nrd3115","article-title":"Biomarkers for Alzheimer\u2019s disease: Academic, industry and regulatory perspectives","volume":"9","author":"Hampel","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.biopsych.2014.08.024_bib49","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1474-4422(08)70019-X","article-title":"Current and future uses of neuroimaging for cognitively impaired patients","volume":"7","author":"Small","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.biopsych.2014.08.024_bib50","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3233\/JAD-130098","article-title":"Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808","volume":"38","author":"Chien","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.biopsych.2014.08.024_bib51","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jalz.2012.11.008","article-title":"[18F] T807, a novel tau positron emission tomography imaging agent for Alzheimer\u2019s disease","volume":"9","author":"Xia","year":"2013","journal-title":"Alzheimer Dement"},{"key":"10.1016\/j.biopsych.2014.08.024_bib52","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00259-012-2261-2","article-title":"Comparison of the binding characteristics of [18F] THK-523 and other amyloid imaging tracers to Alzheimer\u2019s disease pathology","volume":"40","author":"Harada","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.biopsych.2014.08.024_bib53","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.nic.2005.09.007","article-title":"Positron emission tomography diagnosis of Alzheimer\u2019s disease","volume":"15","author":"Coleman","year":"2005","journal-title":"Neuroimaging Clin N Am"},{"key":"10.1016\/j.biopsych.2014.08.024_bib54","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s00259-005-1762-7","article-title":"Brain glucose metabolism in the early and specific diagnosis of Alzheimer\u2019s disease. FDG-PET studies in MCI and AD","volume":"32","author":"Mosconi","year":"2005","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.biopsych.2014.08.024_bib55","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1212\/01.wnl.0000269790.05105.16","article-title":"What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?","volume":"69","author":"Jagust","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.biopsych.2014.08.024_bib56","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1212\/WNL.0b013e3181e8e8b8","article-title":"Comparing predictors of conversion and decline in mild cognitive impairment","volume":"75","author":"Landau","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.biopsych.2014.08.024_bib57","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.exger.2006.05.016","article-title":"Early detection of Alzheimer\u2019s disease using neuroimaging","volume":"42","author":"Mosconi","year":"2007","journal-title":"Exp Gerontol"},{"key":"10.1016\/j.biopsych.2014.08.024_bib58","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1212\/WNL.0b013e3181bc010c","article-title":"Relationships between biomarkers in aging and dementia","volume":"73","author":"Jagust","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.biopsych.2014.08.024_bib59","doi-asserted-by":"crossref","first-page":"878","DOI":"10.2967\/jnumed.108.058529","article-title":"Comparison of 18F-FDG and PiB PET in cognitive impairment","volume":"50","author":"Lowe","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.biopsych.2014.08.024_bib60","doi-asserted-by":"crossref","first-page":"e18111","DOI":"10.1371\/journal.pone.0018111","article-title":"Combined evaluation of FDG-PET and MRI improves detection and differentiation of dementia","volume":"6","author":"Dukart","year":"2011","journal-title":"PLoS One"},{"issue":"pt 10","key":"10.1016\/j.biopsych.2014.08.024_bib61","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1093\/brain\/awm177","article-title":"FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer\u2019s disease","volume":"130","author":"Foster","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.biopsych.2014.08.024_bib62","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1471-2377-9-41","article-title":"Fluorodeoxyglucose-positron emission tomography in the differential diagnosis of early-onset dementia: A prospective, community-based study","volume":"9","author":"Panegyres","year":"2009","journal-title":"BMC Neurol"},{"key":"10.1016\/j.biopsych.2014.08.024_bib63","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2967\/jnumed.109.065870","article-title":"The 18F-FDG PET cingulate island sign and comparison to 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies","volume":"50","author":"Lim","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.biopsych.2014.08.024_bib64","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1007\/s00259-007-0380-y","article-title":"Fully automatic differential diagnosis system for dementia with Lewy bodies and Alzheimer\u2019s disease using FDG-PET and 3D-SSP","volume":"34","author":"Kono","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.biopsych.2014.08.024_bib65","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.neuropharm.2010.04.006","article-title":"Biomarkers in translational research of Alzheimer\u2019s disease","volume":"59","author":"Tarawneh","year":"2010","journal-title":"Neuropharmacology"},{"issue":"suppl 3","key":"10.1016\/j.biopsych.2014.08.024_bib66","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3233\/JAD-2010-100975","article-title":"Alzheimer\u2019s disease: A general introduction and pathomechanism","volume":"22","author":"Finder","year":"2010","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.biopsych.2014.08.024_bib67","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ana.22248","article-title":"Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease","volume":"69","author":"Villemagne","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.biopsych.2014.08.024_bib68","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2967\/jnumed.109.069088","article-title":"In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir)","volume":"51","author":"Wong","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1016\/j.biopsych.2014.08.024_bib69","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jama.2010.2008","article-title":"Use of florbetapir-PET for imaging beta-amyloid pathology","volume":"305","author":"Clark","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.biopsych.2014.08.024_bib70","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ana.22068","article-title":"18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial","volume":"68","author":"Vandenberghe","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.biopsych.2014.08.024_bib71","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1474-4422(11)70077-1","article-title":"Cerebral amyloid-beta PET with florbetaben ((18)F) in patients with Alzheimer\u2019s disease and healthy controls: A multicentre phase 2 diagnostic study","volume":"10","author":"Barthel","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.biopsych.2014.08.024_bib72","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2967\/jnumed.111.094029","article-title":"Clinical validation of 18F-AZD4694, an amyloid-beta-specific PET radioligand","volume":"53","author":"Cselenyi","year":"2012","journal-title":"J Nucl Med"},{"key":"10.1016\/j.biopsych.2014.08.024_bib73","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.2967\/jnumed.109.065284","article-title":"Preclinical properties of 18F-AV-45: A PET agent for Abeta plaques in the brain","volume":"50","author":"Choi","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.biopsych.2014.08.024_bib74","doi-asserted-by":"crossref","first-page":"378","DOI":"10.2967\/jnumed.111.090340","article-title":"Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer\u2019s disease and cognitively normal subjects","volume":"53","author":"Joshi","year":"2012","journal-title":"J Nucl Med"},{"key":"10.1016\/j.biopsych.2014.08.024_bib75","first-page":"1959","article-title":"Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: A comparative analysis","volume":"46","author":"Lopresti","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1016\/j.biopsych.2014.08.024_bib76","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.2967\/jnumed.111.089730","article-title":"Amyloid imaging with 18F-florbetaben in Alzheimer disease and other dementias","volume":"52","author":"Villemagne","year":"2011","journal-title":"J Nucl Med"},{"key":"10.1016\/j.biopsych.2014.08.024_bib77","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/alzrt70","article-title":"PET amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to Alzheimer\u2019s disease","volume":"3","author":"Pontecorvo","year":"2011","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.biopsych.2014.08.024_bib78","doi-asserted-by":"crossref","first-page":"476","DOI":"10.2967\/jnumed.113.120618","article-title":"Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer\u2019s Association","volume":"54","author":"Johnson","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1016\/j.biopsych.2014.08.024_bib79","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s00259-007-0523-1","article-title":"In vivo amyloid imaging with PET in frontotemporal dementia","volume":"35","author":"Engler","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.biopsych.2014.08.024_bib80","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1212\/01.wnl.0000259035.98480.ed","article-title":"11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration","volume":"68","author":"Rabinovici","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.biopsych.2014.08.024_bib81","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/ana.1133","article-title":"Alzheimer\u2019s disease versus dementia with Lewy bodies: Cerebral metabolic distinction with autopsy confirmation","volume":"50","author":"Minoshima","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1016\/j.biopsych.2014.08.024_bib82","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1212\/WNL.47.2.462","article-title":"Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease","volume":"47","author":"Albin","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.biopsych.2014.08.024_bib83","first-page":"280","article-title":"Organic radiopharmaceuticals labeled with short-lived nuclides. 3. 18F-labeled phenylalanines","volume":"12","author":"Hoyte","year":"1971","journal-title":"J Nucl Med"},{"key":"10.1016\/j.biopsych.2014.08.024_bib84","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1474-4422(07)70057-1","article-title":"Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: A phase III, multicentre study","volume":"6","author":"McKeith","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.biopsych.2014.08.024_bib85","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1192\/bjp.bp.108.052050","article-title":"Diagnostic accuracy of 123I-FP-CIT SPECT in possible dementia with Lewy bodies","volume":"194","author":"O\u2019Brien","year":"2009","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.biopsych.2014.08.024_bib86","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1136\/jnnp.2006.110122","article-title":"Dementia with Lewy bodies: A comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy","volume":"78","author":"Walker","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.biopsych.2014.08.024_bib87","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1002\/mds.23393","article-title":"Amyloid imaging of Lewy body-associated disorders","volume":"25","author":"Foster","year":"2010","journal-title":"Mov Disord"},{"key":"10.1016\/j.biopsych.2014.08.024_bib88","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1212\/01.wnl.0000326146.60732.d6","article-title":"Imaging amyloid deposition in Lewy body diseases","volume":"71","author":"Gomperts","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.biopsych.2014.08.024_bib89","unstructured":"FDA prescribing information Amyvid. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/202008s020lbl.pdf. Accessed August 1, 2014."},{"key":"10.1016\/j.biopsych.2014.08.024_bib90","unstructured":"FDA prescribing information Vizamyl. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/203137s000lbl.pdf. Accessed August 1, 2014."},{"issue":"6","key":"10.1016\/j.biopsych.2014.08.024_bib91","first-page":"880","article-title":"Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for \u03b2-amyloid imaging in aging and dementia","volume":"54","author":"Rowe","year":"2013","journal-title":"Jun"}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322314006787?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322314006787?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T14:58:33Z","timestamp":1757775513000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006322314006787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":91,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S0006322314006787"],"URL":"https:\/\/doi.org\/10.1016\/j.biopsych.2014.08.024","relation":{},"ISSN":["0006-3223"],"issn-type":[{"value":"0006-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Imaging Biomarkers Associated With Cognitive Decline: A Review","name":"articletitle","label":"Article Title"},{"value":"Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopsych.2014.08.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}